Paul Zolkind
Papers
1
Total Citations
3
H-Index
1
About
Dr. Paul Zolkind is a leading head and neck surgical oncologist whose research focuses on optimizing treatment for human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma, particularly through transoral robotic surgery (TORS). His major contributions center on refining surgical decision-making to reduce morbidity while maintaining oncologic control. In his highly impactful 2025 study on unilateral versus bilateral TORS for HPV-positive tonsillar cancer, Dr. Zolkind addresses a critical clinical debate: whether to resect the contralateral, clinically uninvolved tonsil. This work provides essential evidence guiding surgeons on when a more conservative, unilateral approach is safe—potentially sparing patients unnecessary surgical morbidity. While a relatively recent publication, its 3 citations already signal growing influence in the field. Dr. Zolkind’s research is characterized by its direct translational impact, bridging surgical technique with patient outcomes. His work is vital reading for any surgeon or researcher navigating the nuances of de-escalation strategies in HPV-positive disease, positioning him as a rising authority in the era of precision surgical oncology.
Research Focus
Key Achievements
Top Papers
- 1